Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Co.'s proprietary technology utilizes Chimeric AutoAntibody Receptor, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Co.'s main CAAR T cell product candidate was designed based on the Chimeric Antigen Receptor, T cell technology that is marketed for the treatment of B cell cancers. Co.'s initial focus is mucosal pemphigus vulgaris, which is an autoimmune blistering disease. The CABA stock yearly return is shown above.
The yearly return on the CABA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CABA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|